X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7344) 7344
Newsletter (63) 63
Magazine Article (13) 13
Newspaper Article (12) 12
Book Chapter (5) 5
Book / eBook (1) 1
Conference Proceeding (1) 1
Government Document (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5793) 5793
life sciences & biomedicine (5408) 5408
humans (3915) 3915
animals (3221) 3221
nitriles (2892) 2892
male (2874) 2874
female (2732) 2732
nitriles - administration & dosage (1736) 1736
nitriles - pharmacology (1672) 1672
rats (1586) 1586
chemistry (1321) 1321
physical sciences (1291) 1291
middle aged (1285) 1285
pharmacology & pharmacy (1228) 1228
nitriles - therapeutic use (1213) 1213
aged (1032) 1032
chemistry, analytical (1032) 1032
adult (1013) 1013
analysis (936) 936
biochemistry & molecular biology (895) 895
oncology (866) 866
triazoles - administration & dosage (840) 840
mass spectrometry (812) 812
mice (796) 796
breast neoplasms - drug therapy (777) 777
treatment outcome (767) 767
liquid chromatography (692) 692
biochemical research methods (653) 653
triazoles - therapeutic use (648) 648
nitriles - adverse effects (647) 647
dose-response relationship, drug (636) 636
time factors (599) 599
methods (564) 564
reproducibility of results (560) 560
rats, sprague-dawley (559) 559
administration, oral (527) 527
breast cancer (517) 517
neurosciences & neurology (501) 501
organic acids (458) 458
research (458) 458
care and treatment (447) 447
pharmacokinetics (447) 447
letrozole (446) 446
neurosciences (445) 445
butadienes - pharmacology (438) 438
endocrinology & metabolism (434) 434
toxicology (428) 428
cancer (421) 421
formic acid (416) 416
nitriles - toxicity (406) 406
chromatography, high pressure liquid - methods (405) 405
rats, wistar (404) 404
aged, 80 and over (402) 402
medicine & public health (397) 397
metabolites (391) 391
antineoplastic combined chemotherapy protocols - therapeutic use (389) 389
enzyme inhibitors - pharmacology (384) 384
tandem mass spectrometry - methods (383) 383
abridged index medicus (379) 379
chromatography (368) 368
nitriles - pharmacokinetics (362) 362
breast neoplasms - pathology (352) 352
triazoles - pharmacology (347) 347
adamantane - analogs & derivatives (345) 345
drug therapy, combination (343) 343
drug administration schedule (334) 334
antineoplastic agents, hormonal - therapeutic use (331) 331
triazoles - adverse effects (323) 323
prostatic neoplasms - drug therapy (322) 322
double-blind method (321) 321
health aspects (321) 321
postmenopause (316) 316
aromatase inhibitors - administration & dosage (308) 308
aromatase inhibitors (306) 306
drug therapy (304) 304
sensitivity and specificity (302) 302
pharmacy (292) 292
aromatase inhibitors - therapeutic use (291) 291
obstetrics & gynecology (289) 289
pregnancy (279) 279
pyrethrins - administration & dosage (278) 278
high performance liquid chromatography (272) 272
anastrozole (269) 269
antineoplastic agents, hormonal - administration & dosage (268) 268
research article (264) 264
disease models, animal (263) 263
ionization (262) 262
cell line, tumor (258) 258
chromatography, liquid - methods (256) 256
anilides - administration & dosage (255) 255
chemotherapy, adjuvant (255) 255
physiological aspects (255) 255
pyrethrins - toxicity (252) 252
tamoxifen - administration & dosage (250) 250
nitriles - chemistry (247) 247
prostate cancer (243) 243
acetonitrile (241) 241
antineoplastic agents - therapeutic use (238) 238
diabetes mellitus, type 2 - drug therapy (238) 238
estrogen (233) 233
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7253) 7253
Japanese (86) 86
German (48) 48
Spanish (31) 31
Russian (28) 28
Chinese (24) 24
French (22) 22
Italian (18) 18
Hungarian (6) 6
Polish (6) 6
Portuguese (6) 6
Norwegian (4) 4
Dutch (2) 2
Swedish (2) 2
Arabic (1) 1
Czech (1) 1
Hebrew (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 01/2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 02/2016, Volume 387, Issue 10020, pp. 760 - 769
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Annals of oncology, ISSN 0923-7534, 02/2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
British journal of haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | Life Sciences & Biomedicine | Hematology | Science & Technology | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Index Medicus | Haematological Malignancy
Journal Article
The lancet oncology, ISSN 1470-2045, 03/2015, Volume 16, Issue 3, pp. 320 - 327
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2013, Volume 368, Issue 14, pp. 1314 - 1325
Despite theoretical benefits of intermittent as compared with continuous androgen-deprivation therapy in patients with metastatic prostate cancer, intermittent... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Confidence Intervals | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis - drug therapy | Penile Erection - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Prostatic Neoplasms - drug therapy | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Survival Analysis | Quality of Life | Aged | Androgen Antagonists - administration & dosage | Nitriles - adverse effects | Usage | Care and treatment | Patient outcomes | Androgen suppression therapy | Drug therapy | Prostate cancer | Methods | Cancer | Statistical analysis | Mental disorders | Prostate-specific antigen | Clinical trials | Patients | Survival | Quality of life | Metastases | Androgens | Castration | Stem cells | Luteinizing hormone | Prostate | Index Medicus | Abridged Index Medicus
Journal Article